Skip to main
  1. Stocks
  2. Zura Bio Ltd
  3. Forecast
ZURA

ZURA Stock Forecast & Price Target

ZURA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zura Bio is viewed favorably because tibulizumab still has meaningful upside in systemic sclerosis, where the biology is better validated and less noisy than hidradenitis suppurativa, with topline Phase II data on-track for 1H27. The company also has a third target in polymyalgia rheumatica, with a Phase 2 start by year-end 2026, a ~N=150-180 patient study, and a large addressable population of ~800k in the US and ~1MM in the EU. Financially, the outlook is supported by a cash position of $2/sh, while the programs are modeled to drive substantial future revenue potential, including 2035E worldwide sales of $1.6B for PMR and peak global revenues of $2.3B for SSc in 2036.

Bears say

Zura Bio is weighed down by tibulizumab’s Phase 2 failure in hidradenitis suppurativa, where the well-powered 247-patient study missed its primary and key secondary endpoints and led management to terminate the HS program, underscoring weak clinical execution risk. The setback is amplified by high placebo response rates and the need to now depend on later-stage readouts in other indications, while the company still faces regulatory, manufacturing, and reimbursement hurdles that could slow or block value creation. Given the stock’s roughly 71% decline versus the XBI’s 3.7% gain, investors are left with a company whose pipeline remains scientifically uncertain and whose commercial prospects remain highly speculative.

ZURA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

ZURA Analyst Forecast & Price Prediction

Get the latest ZURA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ZURA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zura Bio Ltd (ZURA) Forecast

Analysts have given ZURA a Buy based on their latest research and market trends.

According to 4 analysts, ZURA has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zura Bio Ltd (ZURA)


ZURA Analyst Forecast & Price Prediction

Get the latest ZURA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ZURA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ZURA stock data and trends